Vincent R. Zurawski, Jr., Ph.D. President and Chief Executive Officer
Dr. Vincent R. Zurawski, Jr., a pioneer in the biotechnology industry, was a co-founder of Centocor, Inc. and its chief scientific officer for 14 years. He was founder, president and chief executive officer of Apollon, Inc., and chief executive officer of Compugen, Inc., the U.S. subsidiary of Compugen Ltd. He also completed a three-year term as a member of the board of directors of Ricerca Biosciences LLC, an Ohio-based contract research organization (“CRO”). Dr. Zurawski has also recently been a co-founder, past chief executive, chairman of the board of directors, and acting vice president of product development of Avraham Pharamceuticals Ltd., an Israeli company focusing on development of the multifunctional drug, ladostigil, which entered proof-of-concept clinical trials for treatment of both Alzheimer’s disease and mild cognitive impairment (MCI), a condition often seen as a precursor to the development of Alzheimer’s disease. Dr. Zurawski was also a founder, past chief executive, and currently chairman and chief scientific officer of Varinel, Inc., a pharmaceutical company focusing on therapeutic products aimed at treatment of: (1) bacterial infections with a focus on wound healing, (2) disorders of the nervous system, with a particular focus on neurodegenerative disorders, including Parkinson’s and Alzheimer’s disease, and (3) age-related macular degeneration (“AMD”). Dr. Zurawski is also currently a member of the board of directors of DiagnoCure, Inc., a Canadian diagnostics company specializing in development of cancer diagnostic products, and which is traded on the Toronto Stock Exchange. Dr. Zurawski received his Ph.D. in 1973 from Purdue University in West Lafayette, Indiana and completed a post-doctoral research fellowship at the Massachusetts General Hospital and Harvard Medical School before embarking on his business career, for a portion of which he also held a faculty appointment at Harvard Medical School.
John K. McGeehan (Jack) Vice President, Operations
Mr. McGeehan joined Hepregen in March, 2009 with over 25 years of technical and management experience in the biotechnology industry. Mr. McGeehan was a co-founder of ActiMed Laboratories, Inc., a medical device company. While at ActiMed, he invented a novel, patented, non-instrumented clinical chemistry test platform and advanced manufacturing technologies. He was responsible for managing the budget, design, and construction of a $15M computerized, state-of the-art GMP fully automated manufacturing facility. As vice president of operations, Mr. McGeehan guided the development, scale-up, manufacture, and clinical trials, of the ENA•C•T® Total Cholesterol test. Prior to ActiMed, Mr. McGeehan was employed in positions of increasing responsibility at a division of E. Merck. Mr. McGeehan managed the construction and start-up of a $1M dry powder manufacturing facility. He leveraged the fluid bed granulation technology into five distinct diagnostic reagent product lines, taking over 100 products to successful market introductions. Most recently, as a founder of Innova Medical Technologies, Inc., Mr. McGeehan provided general consulting and product development services to medical product companies. Mr. McGeehan holds a B.A. in biology from Millersville University and a M.S. in biomedical engineering from Drexel University. He is named as an inventor on seven US patents.
Mann Shoffner Director, Marketing and Sales
Mr. Shoffner is an experienced sales manager with a 15 year track record in sales, marketing and business development of life sciences companies. He most recently led the commercialization efforts at SRU Biosystems, Inc. For the seven years prior, he established and ran the international sales department for Agencourt Bioscience, Corp., now Beckman Coulter Genomics. Mr. Shoffner holds a M.S. in management of technology from Sloan School at MIT and a B.S. in bioengineering from the University of Pennsylvania.
New Met ID Case Study Released
Ability of a Micropatterned Hepatocyte Co-culture System to Generate Major Human Drug MetabolitesRead More
HepatoPac-Kupffer Cell Inflammation Model
App. Note - A Micropatterned Hepatocyte-Kupffer Cell Co-culture System to Study Inflammation-Drug InteractionsRead More